AP306 125 mg BID for hyperphosphatemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Dec 2024: Trial registered, NCT06712654
  2. 1 Jun 2026: Trial started, NCT06712654

The trials

NCT06712654: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

State
Under way
Phase
Phase 2
People
168 planned
Started
1 Jun 2026
Primary completion
28 Feb 2027
Arms
Cohort 2
Results
None posted
  1. 2 Dec 2024: Trial registered
  2. 1 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.